Mivacurium is a short-acting non-depolarizing neuromuscular blocking agent used to induce anesthesia during intubation and promote skeletal muscle relaxation during surgery or mechanical ventilation. Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant.
- Mechanism
- Curator reviewed
Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
- Primary indication
- For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.Curator reviewed · 5 structured indications
- Formula / weight
- C58H80N2O14 · 1029.2608 g/mol (avg)
- First approval
- Canada, 2012 · United States, 2010
- Code names
- BW-B109OU
Resolves to
ILVYCEVXHALBSC-OTBYEXOQSA-NSMILESCOC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Mivacurium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account